CLINICAL_TRIALS
trial_result
· 2019-08-05
Clinical Trial Update: Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
Summary
Post-marketing assessment report on immunogenicity and safety of Unituxin in high-risk neuroblastoma patients; study terminated with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: United Therapeutics | Conditions: Neuroblastoma | Status: TERMINATED | Results posted: 2019-08-05